| dbo:abstract |
Trifaroten ist ein Retinoid der vierten Generation und wurde im Oktober 2019 in des USA unter dem Namen Aklief zur lokalen Behandlung der Akne vulgaris zugelassen. (de) Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist. Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries. (en) Трифаротен — ретиноид четвёртого поколения, применяемый для лечения акне. Одобрен для применения в США с 2019 года. (ru) |
| dbo:alternativeName |
Aklief (en) |
| dbo:casNumber |
895542-09-3 |
| dbo:chEMBL |
3707313 |
| dbo:drugbank |
DB12808 |
| dbo:fdaUniiCode |
0J8RN2W0HK |
| dbo:kegg |
D11225 |
| dbo:medlinePlus |
a620004 |
| dbo:pubchem |
11518241 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Trifarotene.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/trifarotene |
| dbo:wikiPageID |
62380460 (xsd:integer) |
| dbo:wikiPageLength |
9107 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1098224216 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:United_States_National_Library_of_Medicine dbr:Indication_(medicine) dbc:Pyrrolidines dbr:Orphan_drug dbr:Acne_vulgaris dbr:Agonist dbc:Orphan_drugs dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbc:Benzoic_acids dbc:Anti-acne_preparations dbc:Retinoids dbr:Medication dbr:Topical_medication dbr:Retinoic_acid_receptor_gamma dbr:Retinoid dbr:Topical_administration |
| dbp:atcPrefix |
D10 (en) |
| dbp:atcSuffix |
AD06 (en) |
| dbp:c |
29 (xsd:integer) |
| dbp:casNumber |
895542 (xsd:integer) |
| dbp:chembl |
3707313 (xsd:integer) |
| dbp:chemspiderid |
9693029 (xsd:integer) |
| dbp:class |
Skin and mucous membrane agents (en) |
| dbp:dailymedid |
Trifarotene (en) |
| dbp:drugbank |
DB12808 (en) |
| dbp:h |
33 (xsd:integer) |
| dbp:iupacName |
4 (xsd:integer) |
| dbp:kegg |
D11225 (en) |
| dbp:legalAu |
S4 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:medlineplus |
a620004 (en) |
| dbp:n |
1 (xsd:integer) |
| dbp:o |
4 (xsd:integer) |
| dbp:pregnancyAu |
D (en) |
| dbp:pregnancyCategory |
Contraindicated (en) |
| dbp:pubchem |
11518241 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Topical_administration |
| dbp:smiles |
CCc1ccccc1N1CCCC1 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
MFBCDACCJCDGBA-UHFFFAOYSA-N (en) |
| dbp:synonyms |
CD5789 (en) |
| dbp:tradename |
Aklief (en) |
| dbp:unii |
0 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Dermatologic-drug-stub dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:Acne-treating_agents |
| dcterms:subject |
dbc:Pyrrolidines dbc:Orphan_drugs dbc:Benzoic_acids dbc:Anti-acne_preparations dbc:Retinoids |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Trifaroten ist ein Retinoid der vierten Generation und wurde im Oktober 2019 in des USA unter dem Namen Aklief zur lokalen Behandlung der Akne vulgaris zugelassen. (de) Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist. Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries. (en) Трифаротен — ретиноид четвёртого поколения, применяемый для лечения акне. Одобрен для применения в США с 2019 года. (ru) |
| rdfs:label |
Trifaroten (de) Трифаротен (ru) Trifarotene (en) |
| owl:sameAs |
wikidata:Trifarotene dbpedia-de:Trifarotene dbpedia-ru:Trifarotene https://global.dbpedia.org/id/2YKFF |
| prov:wasDerivedFrom |
wikipedia-en:Trifarotene?oldid=1098224216&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Trifarotene.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Trifarotene |
| is dbo:wikiPageRedirects of |
dbr:C29H33NO4 dbr:Aklief |
| is dbo:wikiPageWikiLink of |
dbr:Vitamin_A dbr:C29H33NO4 dbr:ATC_code_D10 dbr:Acne dbr:Aklief dbr:Retinoid |
| is foaf:primaryTopic of |
wikipedia-en:Trifarotene |
